EGFR Lung Cancer Patient Story

This lung cancer diagnosis at a glance
- Biomarkers
- EGFR mutation
- Sex
- Male
- Treatment
- surveillance
- Outcome
- Care Ongoing
Treatment course, step by step
- After 6 months without active treatment, a PET scan was scheduled for 9 December 2014 to reassess the lung tumor.
- Afatinib was discussed as the likely next treatment if the scan showed progression or metastases.
What happened, in summary
This lung cancer diary entry centers on the anxiety before a PET scan scheduled for December 9, 2014, at Hospital Puerta de Hierro in Majadahonda. The patient had gone 6 months without active treatment while waiting to see how the lung tumor evolved. During that break, symptoms were limited to some cough, mild fatigue, and little else, which gave him hope that the main tumor might be stable or progressing slowly. His biggest fear was metastasis. He described how PET scans can show active cancer cells as bright spots and worried especially about the brain because he had been having more headaches than usual. He also recognized that headaches can come from many causes, including residual nerve pain from herpes zoster, prior chemotherapy effects, stress, and anxiety. The post also notes that he had an EGFR mutation. If the PET scan showed progression or metastases, his oncologist had already discussed Afatinib as a possible next treatment to help prolong life with acceptable quality. That planning gave him one concrete option to hold onto while waiting. As of December 2014, the result was still pending, and the story reflects the emotional strain of waiting for imaging while trying to stay hopeful.
Where this story comes from
This is a lay summary of an account first published by Noxte (Blog Cáncer de Pulmón). Read the original in full
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team.